Digoxin atrial fibrillation
Pro Research Analysisby 
Searched over 200M research papers
Digoxin in Atrial Fibrillation: Efficacy and Risks
Introduction to Digoxin and Atrial Fibrillation
Digoxin is a medication commonly used for rate control in patients with atrial fibrillation (AF). Despite its widespread use, the safety and efficacy of digoxin in AF patients have been subjects of ongoing debate. This article synthesizes recent research findings on the impact of digoxin on clinical outcomes in AF patients.
Digoxin and All-Cause Mortality in Atrial Fibrillation
Increased Mortality Risk
Multiple studies have raised concerns about the association between digoxin use and increased all-cause mortality in patients with AF. A meta-analysis of 37 trials involving 825,061 patients found that digoxin use was associated with a 17% increased risk of all-cause mortality (HR 1.17, 95% CI 1.05 to 1.29) . Another systematic review and meta-analysis of over 200,000 patients confirmed these findings, showing a significant increase in mortality risk associated with digoxin use . These results suggest that digoxin may not be as safe as previously thought, particularly in the long-term management of AF.
Subgroup Analyses
Further analyses have shown that the increased mortality risk persists regardless of whether patients have concomitant heart failure. In patients with AF alone, the hazard ratio for mortality was 1.23 (95% CI 1.17 to 1.30), while in those with both AF and heart failure, the hazard ratio was 1.11 (95% CI 1.06 to 1.16) 47. This indicates that the risks associated with digoxin are not confined to a specific subgroup of AF patients.
Digoxin for Conversion to Sinus Rhythm
Limited Efficacy in Conversion
Several randomized controlled trials have evaluated the efficacy of digoxin in converting recent-onset AF to sinus rhythm. A study involving 36 patients found no significant difference in conversion rates between digoxin and placebo within an 18-hour treatment period . Similarly, another trial with 40 patients reported no substantial advantage of digoxin over placebo in achieving conversion within 12 hours . These findings suggest that digoxin is not effective for converting recent-onset AF to sinus rhythm.
Comparison with Other Treatments
When compared to other medications, digoxin appears less effective. For instance, a study comparing digoxin with propafenone and placebo found that propafenone had significantly higher conversion rates at various time points . This further underscores the limited role of digoxin in rhythm control for AF.
Digoxin for Rate Control
Short-Term Heart Rate Reduction
While digoxin may not be effective for rhythm control, it has shown some efficacy in rate control. A systematic review found that digoxin significantly reduced heart rate compared to placebo within six hours of treatment onset (mean difference -12.0 bpm) . However, it was less effective than beta-blockers, calcium antagonists, and amiodarone in achieving acute heart rate control .
Long-Term Rate Control
Despite its short-term benefits, the long-term efficacy of digoxin for rate control remains unclear. A multicenter trial involving 239 patients found that while digoxin had a rapid effect on heart rate, it did not significantly increase the rate of conversion to sinus rhythm . This suggests that while digoxin can be useful for immediate rate control, its long-term benefits are uncertain.
Quality of Life and Clinical Outcomes
Adverse Clinical Outcomes
In addition to increased mortality, digoxin use has been associated with other adverse clinical outcomes. A study from the ChiOTEAF registry involving elderly Chinese patients found that digoxin use was linked to higher risks of all-cause death, thromboembolism, and worse health-related quality of life . These findings highlight the potential negative impact of digoxin on overall patient well-being.
Conclusion
The current body of evidence suggests that while digoxin may offer short-term benefits in heart rate control for AF patients, it is associated with increased risks of all-cause mortality and other adverse clinical outcomes. Its efficacy in converting AF to sinus rhythm is limited, and it is generally less effective than other medications for both rhythm and rate control. Given these findings, the use of digoxin in AF should be carefully considered, and alternative treatments may be preferable for many patients. Further research is needed to fully understand the long-term effects of digoxin and to identify which patient populations, if any, may benefit from its use.
Sources and full results
Most relevant research papers on this topic
Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo.
Intravenous digoxin offers no substantial advantages over placebo in converting recent onset atrial fibrillation to sinus rhythm and provides weak rate control.
DIGOXIN USE IN ATRIAL FIBRILLATION IS ASSOCIATED WITH INCREASED RISK OF MORTALITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF MORE THAN 200,000 PATIENTS
Digoxin use in atrial fibrillation patients is associated with an increased risk of mortality.
Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation.
Digoxin reduces the frequency of symptomatic atrial fibrillation episodes, but the effect is small and may be due to reduced ventricular rate or irregularity rather than antiarrhythmic action.
Digoxin use and clinical outcomes in elderly Chinese patients with atrial fibrillation: a report from the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry.
Digoxin use in elderly Chinese atrial fibrillation patients is associated with a higher risk of death and worse health-related quality of life.
DOI